Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
30
COEP Quote, Financials, Valuation and Earnings
Last price:
$14.62
Seasonality move
:
2.36%
Day range:
$14.00 - $14.81
52-week range:
$2.31 - $21.41
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
99.79x
P/B ratio:
6.28x
Volume:
193.7K
Avg. volume:
97.2K
1-year change:
407.27%
Market cap:
$78.3M
Revenue:
--
EPS (TTM):
-$3.95
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Coeptis Therapeutics Holdings, Inc. has 309.28% upside to fair value with a price target of -- per share.
COEP vs. S&P 500
-
Over the past 5 trading days, Coeptis Therapeutics Holdings, Inc. has underperformed the S&P 500 by -3.21% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Coeptis Therapeutics Holdings, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Coeptis Therapeutics Holdings, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Coeptis Therapeutics Holdings, Inc. reported revenues of $237.4K.
Earnings Growth
-
Coeptis Therapeutics Holdings, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Coeptis Therapeutics Holdings, Inc. reported earnings per share of -$0.58.
Enterprise value:
73.8M
EV / Invested capital:
--
Price / LTM sales:
99.79x
EV / EBIT:
--
EV / Revenue:
147.28x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-8.84x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$3M
Return On Assets:
-106.16%
Net Income Margin (TTM):
-2727.77%
Return On Equity:
-166.72%
Return On Invested Capital:
-142.92%
Operating Margin:
-1043.39%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $501K | -- | $237.4K | |
| Gross Profit | -$1M | -$1M | -$3M | -$278.2K | -$654.1K | |
| Operating Income | -$21.3M | -$11.3M | -$13.2M | -$2.1M | -$2.5M | |
| EBITDA | -$20.3M | -$10.2M | -$12M | -$1.9M | -$2.2M | |
| Diluted EPS | -$0.93 | -$0.32 | -$3.95 | -$0.05 | -$0.58 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $603.3K | $31K | $1.6M | $1.4M | $6M | |
| Total Assets | $76.4M | $33.3M | $7.2M | $11.1M | $16.3M | |
| Current Liabilities | $46.5K | $1.9M | $2.2M | $3.4M | $2.7M | |
| Total Liabilities | $6.2M | $4.6M | $2.8M | $4M | $3.3M | |
| Total Equity | $70.2M | $28.7M | $4.4M | $7.1M | $13M | |
| Total Debt | -- | -- | $1.3M | $1.8M | $250K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$6.4M | -$6.9M | -$8.4M | -$1.9M | -$2.2M | |
| Cash From Investing | -- | -$100K | $100K | -- | -- | |
| Cash From Financing | $433.7K | $6.7M | $12M | $1.5M | $5.1M | |
| Free Cash Flow | -$6.4M | -$6.9M | -$8.4M | -$1.9M | -$2.2M | |
COEP
Sector
Market Cap
$78.3M
$27.9M
Price % of 52-Week High
68.47%
51.04%
Dividend Yield
0%
0%
Shareholder Yield
-12.12%
-1.49%
1-Year Price Total Return
407.27%
-16.66%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$14.97
200-day SMA
Buy
Level
$12.01
Bollinger Bands (100)
Buy
Level
12.63 - 16.53
Chaikin Money Flow
Sell
Level
-3.3M
20-day SMA
Sell
Level
$16.06
Relative Strength Index (RSI14)
Sell
Level
43.40
ADX Line
Sell
Level
15.8
Williams %R
Neutral
Level
-70.0428
50-day SMA
Sell
Level
$15.49
MACD (12, 26)
Sell
Level
-0.31
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
15.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-14.4987)
Sell
CA Score
(Annual)
Level (-5.2029)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (9.7902)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.
Stock Forecast FAQ
In the current month, COEP has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The COEP average analyst price target in the past 3 months is --.
-
Where Will Coeptis Therapeutics Holdings, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Coeptis Therapeutics Holdings, Inc. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About Coeptis Therapeutics Holdings, Inc.?
Analysts are divided on their view about Coeptis Therapeutics Holdings, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Coeptis Therapeutics Holdings, Inc. is a Sell and believe this share price will drop from its current level to --.
-
What Is Coeptis Therapeutics Holdings, Inc.'s Price Target?
The price target for Coeptis Therapeutics Holdings, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is COEP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Coeptis Therapeutics Holdings, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of COEP?
You can purchase shares of Coeptis Therapeutics Holdings, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Coeptis Therapeutics Holdings, Inc. shares.
-
What Is The Coeptis Therapeutics Holdings, Inc. Share Price Today?
Coeptis Therapeutics Holdings, Inc. was last trading at $14.62 per share. This represents the most recent stock quote for Coeptis Therapeutics Holdings, Inc.. Yesterday, Coeptis Therapeutics Holdings, Inc. closed at $14.66 per share.
-
How To Buy Coeptis Therapeutics Holdings, Inc. Stock Online?
In order to purchase Coeptis Therapeutics Holdings, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get COEP Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
COEP
Sector
P/E ratio
--
23.85x
PEG ratio
0.00x
-0.01x
P/B ratio
6.28x
1.81x
Price / LTM sales
99.79x
1.58x
Growth Metrics
COEP
Sector
Revenue growth
--
4.62%
Earnings growth
-1155%
10.5%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$1.00
-$0.21
Profitability
COEP
Sector
Profitability FY 2024
-$1M
$3.6M
Return on invested capital
-142.92%
-31.87%
Return on assets
-106.16%
-28.18%
Return on equity
-166.72%
-37.63%
Earnings Date
Last Earnings Date
Dec
22
Next Earnings Date
Dec
22
Estimated Next Earnings Date
Mar
23
Balance Sheet
COEP
Sector
Total cash
$5.3M
$26.4M
Short term investments
--
$25.7M
Total assets
$11M
$76.9M
Long term debt
$250K
$3.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
